Nativis Voyager for Newly Diagnosed GBM
This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and temozolomide.
Glioblastoma Multiforme
DEVICE: Nativis Voyager
Treatment-related Adverse Events (Safety), Safety as measured by number of investigational treatment-related adverse events as assessed by CTCAE v4.0., Through study completion, average of 1 year
Clinical Utility PFS, Progression Free Survival, 6 months|Clinical Utility OS, Overall Survival, Through patient completion, expected average 8 months
This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and temozolomide.